Biomolecular Research on Electroconvulsive Therapy for Mental Disorders: State of the Art and Future Directions

References (1)

1. Kellner CH, Obbels J, Sienaert P. When to consider electroconvulsive therapy (ECT). Acta Psychiatr Scand. 2020;141(4):304-315. [CrossRef] 2. Guloksuz S, Rutten BP, Arts B, van Os J, Kenis G. The immune system and electroconvulsive therapy for depression. J ECT. 2014;30(2):132-137. [CrossRef] 3. Atagün Mİ, Canbek ÖA. A systematic review of the literature regarding the relationship between oxidative stress and electroconvulsive therapy. Alpha Psychiatry. 2021. [CrossRef] 4. van Buel EM, Patas K, Peters M, Bosker FJ, Eisel UL, Klein HC. Immune and neurotrophin stimulation by electroconvulsive therapy: is some inflammation needed after all? Transl Psychiatry. 2015;5(7):e609. [CrossRef] 5. van Zutphen EM, Rhebergen D, van Exel E, et al. Brain-derived neurotrophic factor as a possible predictor of electroconvulsive therapy outcome. Transl Psychiatry. 2019;9(1):155. [CrossRef] 6. Argyelan M, Lencz T, Kang S, et al. ECT-induced cognitive side effects are associated with hippocampal enlargement. Transl Psychiatry. 2021;11(1):516. [CrossRef] 7. Van Den Bossche MJA, Emsell L, Dols A, et al. Hippocampal volume change following ECT is mediated by rs699947 in the promotor region of VEGF. Transl Psychiatry. 2019;9(1):191. [CrossRef] 8. Bartoli F, Cioni RM, Callovini T, Cavaleri D, Crocamo C, Carrà G. The kynurenine pathway in schizophrenia and other mental disorders: insight from meta-analyses on the peripheral blood levels of tryptophan and related metabolites. Schizophr Res. 2021;232:61-62. [CrossRef]. 9. Bartoli F, Misiak B, Callovini T, et al. The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites. Mol Psychiatry. 2021;26(7):3419-3429. [CrossRef] 10. Guloksuz S, Arts B, Walter S, et al. The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway. Brain Behav Immun. 2015;48:48-52. [CrossRef]